Saturday, October 1, 2022


Biotechnology News Magazine

Bal Johal Is Appointed New Director of Research and Development at Owen Mumford

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Bal Johal brings a wealth of experience in the pharmaceutical and medical device sector, covering a range of therapeutic areas and dosage forms, most recently working as vice president of product development, quality, regulatory and medical with Circassia.

Prior to this, Bal Johal had roles within research and development at GlaxoSmithKline, Pfizer and Mundipharma Research Ltd.

Research and development has always been at the heart of Owen Mumford’s unique offer and represents a major pillar in the company’s strategic direction and development. The appointment of Johal into this pivotal role will enhance the quality and strength of the company’s existing pipeline. It also secures a well-defined path to deliver new ambitions in innovation, sustainable product design, life-cycle analysis and increased positive impact on healthcare professional and patient experience.

“We welcome Bal very warmly into our business,” said Jarl Severn, Managing Director at Owen Mumford. “She has the background, experience and drive to continue to accelerate the innovation and forward-thinking that will see us achieve ambitious growth and set us apart from the competition.”

Commenting on her appointment, Bal Johal said, “To join Owen Mumford at this time is very exciting. With a combination of progress already made and some very talented people within the organisation, I can see that we will be able to deliver a high standard of success and innovation that will have a truly positive impact.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine